Suven Pharmaceuticals Q2 FY25 revenue grows 12% in Q2
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
Construction of the plant will commence in 2025 with first production expected to be in 2027
Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore
Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
Hospital business revenues increase 13.9% to Rs. 1,655 crore
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
Subscribe To Our Newsletter & Stay Updated